Is there a circadian variation in 5-Fluorouracil (5FU) plasma concentration (Cp) given by continuous infusion?

被引：0
|
作者：
Strocchi, E
Camaggi, CM
Martoni, A
Sereni, A
Pannuti, R
Pittureri, C
Cacciari, N
Zamagni, C
Pannuti, F
机构：
[1] ANT Lab, Dept Organ Chem, Bologna, Italy
[2] S Orsola M Malpighi Hosp, Div Med Oncol, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
243P
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [41] EXAMINATION OF DIRECT CARDIAC EFFECTS OF 5-FLUOROURACIL (5FU) IN THE ISOLATED DOG HEART
    HERMAN, E
    WARAVDEKAR, N
    YOUNG, R
    KROP, S
    PHARMACOLOGIST, 1979, 21 (03): : 162 - 162
  • [42] PHARMACOKINETICS AND PHARMACODYNAMICS OF LOCOREGIONAL 5-FLUOROURACIL (5FU) IN ADVANCED COLORECTAL LIVER METASTASES
    GOLDBERG, JA
    KERR, DJ
    WILLMOTT, N
    MCKILLOP, JH
    MCARDLE, CS
    BRITISH JOURNAL OF CANCER, 1988, 57 (02) : 186 - 189
  • [43] 5-Fluorouracil (5FU) intratumoural pharmacokinetics: Rapid uptake in cells and in spheroids (SPH)
    Jove, M.
    Loadman, P.
    Wicks, J.
    Spencer, J.
    Race, A.
    Salazar, R.
    Twelves, C. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] A COMMON CULPRIT AND AN IRISH DELAY: 5-FLUOROURACIL (5FU) INDUCED TRANSIENT MYOCARDITIS
    McKittrick, Myles
    McKittrick, Seoidin Elizabeth
    Gallen, Rory
    Fitzhenry, Niamh
    Millar, Kevin
    O'Hanlon, Rory
    Waterhouse, Deirdre
    Brennan, Alice
    Abbas, Syed F.
    Hennessy, Terence
    Arnous, Samer
    Ullah, Ihsan
    Muradagha, Hani
    Kiernan, Thomas
    Tuohy, Stephen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 2642 - 2642
  • [45] The impact of sarcopenia on toxicity and pharmacokinetics of 5-fluorouracil (5FU) in colorectal cancer.
    Williams, Grant Richard
    Deal, Allison Mary
    Shachar, Shlomit S.
    Walko, Christine Marie
    Patel, Jai Narendra
    O'Neil, Bert H.
    McLeod, Howard L.
    Weinberg, Marc
    Choi, Seul Ki
    Muss, Hyman B.
    Sanoff, Hanna Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor
    Peters, GJ
    van Groeningen, CJ
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) : 4267 - 4268
  • [47] CIRCADIAN-RHYTHM OF 5-FLUOROURACIL (FU) PHARMACOKINETICS AND TOLERANCE
    NOWAKOWSKADULAWA, E
    CHRONOBIOLOGIA, 1990, 17 (01) : 27 - 35
  • [48] PHARMACOKINETIC MODULATION OF PLASMA 5-FLUOROURACIL CONCENTRATIONS TO POTENTIATE THE ANTITUMOR-ACTIVITY OF CONTINUOUS VENOUS INFUSION OF 5-FLUOROURACIL
    FUJII, S
    FUKUSHIMA, M
    SHIMAMOTO, Y
    SHIRASAKA, T
    JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (06): : 509 - 512
  • [49] Effect of 5-fluorouracil (5-FU) infusion in myocardial perfusion scans
    Bishiniotis, T
    Mouratidou, D
    Pentheroudakis, G
    Andreadis, C
    Katseas, G
    Litos, A
    Hatseras, D
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 60 - 60
  • [50] PHARMACOKINETIC PROFILE OF DOXIFLURIDINE (5'-DFUR, FURTULONR), A 5-FLUOROURACIL (5FU) PRO-DRUG
    HEINTZ, RC
    GUNTERT, TW
    SUTTER, C
    LINDERCICCOLUNGHI, SN
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 207 - 207
12345